Plasma biomarkers for predicting heart failure in patients with acute myocardial infarction

Rong Guihong1, Wang Xiao1, Qin Xinling1

  • 1Affiliated Hospital of Guilin Medical University, Department of Clinical Laboratory, Guilin, China.

PubMed

Insights

Biomarkers like NT-proBNP, NLR, and GDF-15 can predict heart failure (HF) after acute myocardial infarction (AMI). Early identification of these HF biomarkers aids in developing timely therapeutic strategies for better patient outcomes.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Clinical Prognostics

Background:

  • Heart failure (HF) post-acute myocardial infarction (AMI) leads to high mortality.
  • Timely revascularization is crucial for managing post-AMI HF.
  • Predictive value of biomarkers like NT-proBNP, cTNT, PLR, NLR, and GDF-15 for post-AMI HF requires further investigation.

Purpose of the Study:

  • Identify potent biomarkers for prognosing HF development after AMI.
  • Devise early interception and therapeutic strategies for post-AMI HF.
  • Evaluate the predictive accuracy of NT-proBNP, cTNT, PLR, NLR, and GDF-15 in post-AMI HF patients.

Main Methods:

  • 170 AMI patients were enrolled (44 with post-AMI HF, 126 without).
  • Serum biomarkers (NT-proBNP, cTNT, PLR, NLR, GDF-15) were measured using ELISA.
  • T-tests were employed to assess the predictive value of biomarkers for post-AMI HF.

Main Results:

  • NT-proBNP, GDF-15, and NLR levels were significantly higher in the HF group.
  • PLR levels did not differ significantly between groups.
  • NT-proBNP demonstrated the highest predictive value (AUC=0.82), followed by GDF-15 (AUC=0.661) and NLR (AUC=0.632).

Conclusions:

  • NT-proBNP, NLR, and GDF-15 are valuable biomarkers for predicting HF post-AMI.
  • These biomarkers can aid in early risk stratification and management of post-AMI HF.
  • Further research may refine therapeutic strategies based on these predictive markers.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
81
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
41
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K